🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

  2. Epcoritamab (GEN3013), Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Epcoritamab (GEN3013), Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  3. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  4. Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  5. Erleada 240 mg film-coated tablets, Erleada 60 mg film-coated tablets, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Disc Medicine

    Metastatic hormone-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  6. FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  7. FLUOROURACIL, CISPLATIN, CAPECITABINE, CISPLATIN, TRASTUZUMAB, Placebo for Pembrolizumab, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, TRASTUZUMAB

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  8. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  9. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  10. Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

    Sanofi-aventis Healthcare Pty Ltd

    Fabry’s disease

    phase 3 small molecule active

    1 trial

  11. Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Ningbo Cancer Hospital

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

  12. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion

    AXIM BIOTECHNOLOGIES, INC.

    B-cell Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  14. Fortecortin® 2 mg Tabletten, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, KIOVIG 100 mg/ml solution for infusion, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infusion, Pomalidomide, KIOVIG 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, KIOVIG 100 mg/ml solution for infusion, Pomalidomide, Dexamethasone Tablets BP 2.0mg, JNJ-64407564, JNJ-64407564, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, Dexamethas

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. Fortecortin® 2 mg Tabletten, teclistamab, Lenalidomide Mylan 25 mg hard capsules, JNJ-64407564, Dexamethasone Tablets BP 2.0mg, Lenalidomide Accord 10 mg hard capsules, JNJ-64407564, Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Mylan 5 mg hard capsules, Privigen 100 mg/ml solution for infusion, DARZALEX 1800 mg solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Privigen 100 mg

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  16. GEMCI-cell® 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Gemcitabine 1 g Powder for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Carbomedac® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusio

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  17. GEMCITABINE , Tecentriq, PEMETREXED , VINORELBINE , CISPLATIN , DOCETAXEL , Tecentriq 1,200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. GEMCITABINE, INFLIXIMAB, CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, Rilvegostomig

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  19. GENTAMICIN , CEFAZOLIN , VANCOMYCIN , TEDIZOLID , PRISTINAMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM , CEFOTAXIME, CEFTAROLINE FOSAMIL , AMOXICILLIN , OFLOXACIN , CLINDAMYCIN , TIGECYCLINE , LINEZOLID , AMIKACIN , LYMECYCLINE , CEFTRIAXONE , TEICOPLANIN , DOXYCYCLINE , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , Xydalba 500 mg powder for concentrate for solution for infusion, LEVOFLOXACIN , DELAFLOXACIN , CIPROFLOXACIN , CLOXACILLIN , OXACILLIN , DAPTOMYCIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , RIFAMP

    Pari Pharma GmbH

    Catheter related bloodstream infections due to Staphylococcus aureus

    phase 3 small molecule active

    1 trial

  20. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  21. Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  22. Gazyvaro 1,000 mg concentrate for solution for infusion., Chlorambucil 2 mg tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclexta, Venclyxto, Venclexta, Venclyxto, Venclexta, Venclyxto

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  23. Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln

    Hoffmann-La Roche

    Primary Membranous Nephropathy (pMN)

    phase 3 small molecule active

    1 trial

  24. Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources